1. At a Glance
Aurobindo Pharma’s Q2FY26 results are out — and let’s just say the Hyderabad pharma giant continues its “generics royalty” reign with the calm arrogance of a company that files ANDAs like the rest of us send WhatsApp forwards. The company clocked a revenue of ₹8,286 crore and a net profit of ₹848 crore, marking a modest 6.3% YoY growth in sales and a 3.8% rise in profit. The Operating Profit Margin stayed steady at 20%, proving that even in a world of patent cliffs and FDA inspections, Aurobindo can still squeeze decent margins out of paracetamol and penicillin.
At a market cap of ₹67,330 crore and a P/E of 19.7x, it’s cheaper than its more glamorous peers but definitely not a “penny stock” drug dealer. The ROCE stands at 14.2%, while ROE lingers at 11.1% — a mix of efficiency and “R&D hangover.” The debt is ₹8,263 crore with a D/E ratio of 0.25, meaning the balance sheet is sturdy enough to survive another FDA observation or two.
And speaking of those, the quarter was a reality show: two Form 483s, a $250M US acquisition (Lannett), and 7 ANDA approvals. Who says pharma is boring?
2. Introduction
Aurobindo Pharma has perfected the art of selling off-patent molecules to the world while surviving periodic FDA heart attacks. It’s the kind of company that can take an antibiotic older than your dad’s Nokia 3310 and still make crores out of it — all while juggling 29 plants, 150 countries, and regulators breathing down its neck.
From ARVs for Africa to ADHD drugs for America, this Hyderabad-based empire has built its fortunes on being India’s most consistent pharmaceutical exporter. Yet, its stock has been as moody as a teenager on exam day — down 18% in the past year, even though its 3-year return is a healthy 27.6%. Investors don’t seem sure whether to call it a comeback or a caffeine crash.
The real kicker? Just when it looked like a boring “generic machine,” Aurobindo decided to flex its innovation muscle. Its biologics arm, CuraTeQ, pulled off multiple biosimilar approvals from the UK’s MHRA and Europe’s EMA — from trastuzumab (Dazublys) to Dyrupeg and Zefylti. If these names sound like Marvel villains, that’s because they kind of are — they might actually save Aurobindo’s next growth chapter.
But the FDA never sleeps. Between August and September 2025, Aurobindo collected more Form 483s than medals in a school sports day — 8 for Unit XII and 5 for its Apitoria subsidiary. None were “data integrity” issues (the pharma world’s equivalent of a felony), but still, it’s not exactly a compliment.
So the question is: is Aurobindo scripting a biosimilar rebirth, or just another sequel in its long-running generics soap opera?
3. Business Model – WTF Do They Even Do?
If you’ve ever swallowed a pill with a name ending in “-zole” or “-mab,” chances are Aurobindo was somewhere in the supply chain, quietly billing dollars.
The company’s business model runs on two engines:
A) Formulations (87% of Q3 FY25 revenue):
This is where the real money is — tablets, capsules, syrups, and injectables that target the big therapeutic gangs: CNS, cardiovascular, anti-retroviral, gastrointestinal, diabetic, and allergy segments. In other words, everything from depression to indigestion.
Aurobindo’s US business alone contributes 53% of total revenue, while Europe adds 30%, Growth Markets (Latin America, Africa, Asia) give 13%, and the ARV segment contributes 4%. It’s like an Indian wedding buffet — a bit of everything, but America gets the biggest plate.
In the US, generic orals dominate (68%), while injectables and specialty now form 18%, showing the gradual shift from cheap copycats to complex generics
